Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBYN DAWN HARTVICKSON

Allopathic & Osteopathic Physicians Family Medicine

NPI
1679532659
CMS profile
303021
Location
NEWTON, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$349.87

24 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $349.87 24

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBYN DAWN HARTVICKSON

NPI 1679532659 · CMS profile ID 303021

Allopathic & Osteopathic Physicians / Family Medicine

NEWTON, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679532659?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679532659?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679532659?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1679532659?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

24 matching records · $349.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 24 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–24 of 24.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $13.6112/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658119713 CMS
Amgen Inc. $17.8611/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662960821 CMS
PFIZER INC. $11.9611/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673713099 CMS
Amarin Pharma Inc. $16.0811/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699249353 CMS
PFIZER INC. $13.3110/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673144925 CMS
Mylan Specialty L.P. $11.3110/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694796491 CMS
Astellas Pharma US Inc $14.3310/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655596031 CMS
AstraZeneca Pharmaceuticals LP $10.9009/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685550683 CMS
Astellas Pharma US Inc $14.7809/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655596027 CMS
Merck Sharp & Dohme Corporation $9.6308/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695723979 CMS
Astellas Pharma US Inc $13.9807/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655596025 CMS
Amgen Inc. $19.3206/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662960817 CMS
PFIZER INC. $12.7505/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672101183 CMS
Bayer HealthCare Pharmaceuticals Inc. $10.9505/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628421417 CMS
Radius Health, Inc. $12.0905/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683951475 CMS
Amgen Inc. $15.5604/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662960813 CMS
Lilly USA, LLC $17.0504/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658137539 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.4304/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700242137 CMS
Allergan Inc. $12.9403/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670501485 CMS
Lilly USA, LLC $18.6402/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658120691 CMS
PFIZER INC. $14.5902/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671933799 CMS
Astellas Pharma US Inc $17.2702/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655596023 CMS
Merck Sharp & Dohme Corporation $12.2901/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695258567 CMS
Flexion Therapeutics, Inc. $24.2401/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705850477 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $349.87 24
PY2020 $259.38 18
PY2021 $867.92 59
PY2022 $1,012.70 73
PY2023 $2,574.33 71
PY2024 $862.16 54
PY2025 $813.93 47

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $136,207.90 39
PY2024 Principal investigator $344,898.92 54
PY2023 Principal investigator $702,129.77 95
PY2022 Principal investigator $153,146.27 62
PY2021 Principal investigator $143,310.07 45
PY2020 Principal investigator $223,270.91 168
PY2019 Principal investigator $302,825.41 141

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $119.46 12/31/2022 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 940393585
Principal investigator 1 PFIZER INC. $3,217.73 12/30/2022 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949771129
Principal investigator 1 ModernaTX, Inc. $1,395.00 12/23/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963641263
Principal investigator 1 Organon LLC $2,270.70 12/22/2022 Non-covered Recipient Entity
Alliance for Multispecialty Research, LLC
OG-8175A-023 No dispute reported 06/30/2026 938724069
Principal investigator 1 ModernaTX, Inc. $2,405.00 12/21/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963641261
Principal investigator 1 ModernaTX, Inc. $1,500.00 12/09/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963641257
Principal investigator 1 PFIZER INC. $754.07 12/07/2022 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949771131
Principal investigator 1 ModernaTX, Inc. $2,839.85 11/25/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963641137
Principal investigator 1 Organon LLC $4,343.40 11/23/2022 Non-covered Recipient Entity
Alliance for Multispecialty Research, LLC
OG-8175A-023 No dispute reported 06/30/2026 938724067
Principal investigator 1 GlaxoSmithKline, LLC. $1,598.40 11/09/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954005
Principal investigator 1 GlaxoSmithKline, LLC. $220.00 11/09/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954029
Principal investigator 1 ModernaTX, Inc. $6,032.95 11/02/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963641133
Principal investigator 1 ModernaTX, Inc. $529.15 10/26/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, No dispute reported 06/30/2026 963640947
Principal investigator 1 Organon LLC $3,756.60 10/26/2022 Non-covered Recipient Entity
Alliance for Multispecialty Research, LLC
OG-8175A-023 No dispute reported 06/30/2026 938724065
Principal investigator 1 PFIZER INC. $5,049.40 10/25/2022 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949798323
Principal investigator 1 ModernaTX, Inc. $200.00 10/12/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963640945
Principal investigator 1 GlaxoSmithKline, LLC. $1,007.10 10/03/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954033
Principal investigator 1 ModernaTX, Inc. $7,362.95 10/03/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963640941
Principal investigator 1 PFIZER INC. $754.07 09/22/2022 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949798325
Principal investigator 1 GlaxoSmithKline, LLC. $1,300.50 09/14/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954003
Principal investigator 1 ModernaTX, Inc. $4,235.30 09/07/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963257965
Principal investigator 1 ModernaTX, Inc. $529.15 08/29/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, No dispute reported 06/30/2026 963258031
Principal investigator 1 ModernaTX, Inc. $250.00 08/24/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963257925
Principal investigator 1 GlaxoSmithKline, LLC. $3,499.99 08/17/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 943954035
Principal investigator 1 ModernaTX, Inc. $897.50 08/17/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, No dispute reported 06/30/2026 963258043
Principal investigator 1 ModernaTX, Inc. $8,922.35 08/10/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963257995
Principal investigator 1 PFIZER INC. $2,793.19 08/05/2022 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949804327
Principal investigator 1 ModernaTX, Inc. $1,058.30 07/27/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, No dispute reported 06/30/2026 963258049
Principal investigator 1 PFIZER INC. $1,892.40 07/09/2022 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949806791
Principal investigator 1 ModernaTX, Inc. $150.00 07/08/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, No dispute reported 06/30/2026 963258001
Principal investigator 1 ModernaTX, Inc. $195.00 07/08/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, No dispute reported 06/30/2026 963258007
Principal investigator 1 ModernaTX, Inc. $17,437.45 07/08/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, No dispute reported 06/30/2026 963258083
Principal investigator 1 GlaxoSmithKline, LLC. $110.00 07/06/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954009
Principal investigator 1 GlaxoSmithKline, LLC. $1,031.40 07/06/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954023
Principal investigator 1 ModernaTX, Inc. $1,000.00 07/06/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963257937
Principal investigator 1 ModernaTX, Inc. $2,000.00 07/06/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963257949
Principal investigator 1 ModernaTX, Inc. $3,133.75 07/06/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963257953
Principal investigator 1 ModernaTX, Inc. $7,500.00 07/06/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963257989
Principal investigator 1 ModernaTX, Inc. $6,620.00 07/06/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, No dispute reported 06/30/2026 963258073
Principal investigator 1 GlaxoSmithKline, LLC. $5,873.14 06/27/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 943954037
Principal investigator 1 GlaxoSmithKline, LLC. $1,089.90 06/22/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954011
Principal investigator 1 GlaxoSmithKline, LLC. $1,823.40 06/08/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954001
Principal investigator 1 GlaxoSmithKline, LLC. $1,802.70 06/08/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954015
Principal investigator 1 GlaxoSmithKline, LLC. $1,849.50 06/08/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954027
Principal investigator 1 GlaxoSmithKline, LLC. $1,007.10 06/08/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954031
Principal investigator 1 PFIZER INC. $754.07 06/07/2022 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949813843
Principal investigator 1 PFIZER INC. $3,784.80 05/21/2022 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949752795
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 04/20/2022 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
Safety, Immunogenicity, Infectivity, and Dose-Finding Study of an Investigational Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers No dispute reported 06/30/2026 935561323
Principal investigator 1 PFIZER INC. $3,350.69 04/08/2022 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949822907
Principal investigator 1 PFIZER INC. $1,892.40 03/16/2022 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949827189
Principal investigator 1 Allergan, Inc. $1,192.60 03/08/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC DBA N
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 864373375
Principal investigator 1 PFIZER INC. $4,556.42 03/04/2022 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949827441
Principal investigator 1 PFIZER INC. $2,610.13 03/03/2022 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949827443
Principal investigator 1 GlaxoSmithKline, LLC. $110.00 02/01/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954013
Principal investigator 1 GlaxoSmithKline, LLC. $110.00 02/01/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954019
Principal investigator 1 GlaxoSmithKline, LLC. $110.00 02/01/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954021
Principal investigator 1 PFIZER INC. $5,450.71 01/25/2022 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949831689
Principal investigator 1 GlaxoSmithKline, LLC. $1,534.50 01/24/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954007
Principal investigator 1 GlaxoSmithKline, LLC. $1,493.10 01/24/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954017
Principal investigator 1 GlaxoSmithKline, LLC. $110.00 01/24/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 943954025
Principal investigator 1 ModernaTX, Inc. $500.00 01/05/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, No dispute reported 06/30/2026 963258019
Principal investigator 1 ModernaTX, Inc. $1,229.00 01/05/2022 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, No dispute reported 06/30/2026 963258055